Fate Therapeutics price to sales ratio FATE

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 38.9×
7-year median: 28.8×
Against its 7-year history: 60th; percentile: 0 is its lowest day, 100 its highest
7-year range: 1.4× to 198×
Peer median: 3.6×

Fate Therapeutics' price to sales ratio is 38.9× as of Oct 23, 2026.

That is above its 7-year median of 28.8×, close to the middle of its last 7 years.

Over that time it ranged from 1.4× in Oct 2023 to 198× in Jun 2021.

The median for 4 biotech stocks of a similar size is 3.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	38.9×	15.9×	57.2×
2025	16.2×	6.3×	22.5×
2024	13.6×	3.5×	95.6×
2023	3.5×	1.4×	9.7×
2022	14.2×	14.2×	84.4×
2021	102×	83.8×	198×
2020	189×	147×	194×
2019	156×	108×	198×

Against its peers

Companies in Biotechnology nearest Fate Therapeutics' size, closest first, today.

Company	Price to sales ratio
FATEFate Therapeutics	38.9×
PLXProtalix BioTherapeutics	2.5×
MGTXMeiraGTx	2.2×
VCELVericel	7.1×
ADMAAdma Biologics	4.7×
Peer median	3.6×

Where Fate Therapeutics ranks

#59of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Fate Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.